Publications

Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients 2 to 5 Years of Age with Mild to Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial

Roflumilast Foam 0.3% Once Daily in Patients With Seborrheic Dermatitis: Improvement in Patient-Reported Outcomes and Pruritus From a Phase 3 Trial (STRATUM)

Pooled Efficacy, Patient-Reported Outcomes, and Safety of Roflumilast Cream 0.15% From the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Clinical Trials of Adults and Children With Atopic Dermatitis

Roflumilast Cream 0.3% in Patients With Psoriasis: Improvement in Patient-Reported Outcomes and Pruritus From Two Pooled Phase 3 Trials (DERMIS-1/DERMIS-2)

Patient-Reported Outcomes With Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis in the Phase 3 ARRECTOR Trial

Clinical Efficacy and Patient-Reported Impacts of Roflumilast Foam 0.3% In Seborrheic Dermatitis: An Analysis Of STRATUM Data For Patients Unresponsive Or Intolerant To Topical Corticosteroids

Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient PASI and PASI-HD Responses: Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials

Roflumilast Cream 0.15% in Patients With Atopic Dermatitis: Individual Patient EASI Responses: Pooled INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials

ARQ-234: A High-Affinity CD200-Fc Fusion Protein for the Treatment of Atopic Dermatitis